- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04495322
To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.
A Phase 1, Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and to Evaluate the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase 1, single-center, randomized, double-blind, placebo-controlled, single-dose escalation study to evaluate the safety, tolerability, and pharmacokinetics profiles of TG-1000 in healthy volunteers, and to evaluate the food effect on pharmacokinetics of single oral dose of TG-1000 in healthy volunteers. The study will be divided into two parts.
Part A is designed as randomized, double-blind, placebo-controlled, sequential, single ascending oral dose to evaluate the safety, tolerability, and PK profiles of TG-1000 in healthy volunteers.
Part B is designed as randomized, open-label, two treatment (fasted vs. fed), two-period, two-sequence crossover to compare the effects of food on the Pharmacokinetic (PK) of single oral dose of TG-1000 in healthy subjects.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Hunan
-
Changsha, Hunan, China
- Xiangya Hospital of Central South University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing to provide written informed consent.
- Age 18 (or legal adult age) to 45 years.
- Body mass index (BMI) in the range of ≥19.0 to ≤ 24.0 kg/m2 and body weight ≥ 50 kg for male and ≥ 45 kg for female at Screening.
- Subjects have good communication with Investigator and agree to follow the study requirement to complete study.
Exclusion Criteria:
- Clinically significant abnormality in 12-lead ECG, chest X-ray, abdominal ultrasounds, physical examination, vital signs or laboratory values at Screening or Day-1.
- Positive breath alcohol or urine drug tests at Day-1.
- Positive test results for Immunoglobulin M anti-HAV antibody, HBsAg, anti-HCV antibody, HIV or syphilis at Screening.
- Female subjects with positive pregnancy test results at Screening or Day-1.
- Male subjects are unwilling to use effective contraception and refrain from sperm donation from Screening until 3 months after the study drug administration.
Current or prior history of any of the following:
- Significant cardiac disease, diabetes, liver, kidney disease, psychiatric diseases or drug abuse or diseases that will affect immunity.
- Difficulty in swallow or gastrointestinal disorder that could interfere with the absorption of the study drug
- Difficulty in blood sampling or venipuncture
- Drug allergy or hypersensitivity
- Blood donation ≥ 400 mL within 3 months before and after study.
- Alcoholics or frequent drinkers prior to Screening.
- Frequent smokers prior to Screening.
Use of any prohibited medications or surgeries prior to study drug administration:
a. Received any other investigational agents or devices, liver enzyme inducer or inhibitors, medications including prescriptions, non-prescriptions or herbal remedies, dietary supplements or surgeries.
- Unwilling to abstain from alcohol, tobacco, nicotine containing products, caffeine- or xanthine-containing beverages from Screening until discharge from the phase I unit.
- Subjects may not be qualified for the study judged by the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 10 mg TG-1000
Eligible subjects will receive single oral dose of study drug (2 x 5-mg TG-1000 capsules)on Day 1 under fasted condition.
|
Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
|
EXPERIMENTAL: 20 mg TG-1000 or Placebo
Eligible subjects will receive single oral dose of study drug (20 mg TG-1000 capsule or Placebo capsule) on Day 1 under fasted condition.
|
Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
|
EXPERIMENTAL: 40 mg TG-1000 or Placebo
Eligible subjects will receive single oral dose of study drug (2 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
|
Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
|
EXPERIMENTAL: 80 mg TG-1000 or Placebo
Eligible subjects will receive single oral dose of study drug (4 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
|
Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
|
EXPERIMENTAL: 120 mg TG-1000 or Placebo
Eligible subjects will receive single oral dose of study drug (6 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
|
Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
|
EXPERIMENTAL: 160 mg TG-1000 or Placebo
Eligible subjects will receive single oral dose of study drug (8 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
|
Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
|
EXPERIMENTAL: X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed)
Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected.
Subject will receive a single oral dose of TG-1000 under fasted condition.
After washout period, subject will receive a single oral dose of TG-1000 under fed condition.
|
Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
|
EXPERIMENTAL: X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)
Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected.
Subject will receive a single oral dose of TG-1000 under fed condition.
After washout period, subject will receive a single oral dose of TG-1000 under fasted condition.
|
Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects of treatment-emergent adverse events
Time Frame: 8 days
|
Any significant findings after dosing will be considered as adverse events.
|
8 days
|
Number of subjects of Significant Abnormal Vital Signs Findings
Time Frame: 8 days
|
The systolic and diastolic blood pressure (mmHg), pulse/heart rate (beats/min), respiratory rate (breaths/min), and body temperature (oC) will be measured.
|
8 days
|
Number of subjects With Significant Abnormal Physical Examination Findings
Time Frame: 8 days.
|
A full general physical examination of the major body systems (General Appearance; Dermatological including skin and nails; Head and Neck; Chest region including Heart and Lung; Abdominal region including Gastrointestinal and Gastroenterology; Back region; Extremities; Psychiatric or Neurological; Lymph nodes; Other) will be performed by investigator.
|
8 days.
|
Number of subjects With Significant Abnormal 12-lead Electrocardiography (ECG) Findings
Time Frame: 8 days
|
12-lead ECG will be performed after a rest in a supine position.
The following ECG parameters will be listed: heart rate, the time between QRS complexes (RR Interval) (ms), the beginning of the P wave to the first deflection of the QRS complex (PR Interval) (ms), first deflection of QRS complex to end of QRS complex at isoelectric line (QRS duration) (ms), first deflection of QRS complex to end of T wave at isoelectric line (QT interval) (ms), Corrected QT interval by Bazett (QTcB) (ms), and Corrected QT interval by - Fridericia (QTcF) (ms).
|
8 days
|
Number of subjects With Significant Abnormal Holter Electrocardiography (ECG) Findings
Time Frame: 12 hr pre-dose until 24 hr post-dose
|
Holter ECG will be monitor continue from 12 hr pre-dose until 24 hr post-dose.
The Investigator will determine whether the results of the Holter monitoring are normal or abnormal.
|
12 hr pre-dose until 24 hr post-dose
|
Number of Participants With Significant Abnormal Laboratory Values
Time Frame: 8 days
|
Chemistry, Hematology, Coagulation, Urinalysis, Human Immunodeficiency Virus (HIV) test, Hepatitis A virus(HAV) test, Hepatitis B virus (HBV) test, Hepatitis C virus (HCV) test, syphilis, serum pregnancy tests and Breath Alcohol Test
|
8 days
|
Peak Plasma Concentration (Cmax)
Time Frame: 15 days
|
Blood sample will be collected to evaluate PK profile and food effect of TG-1000.
|
15 days
|
time to Cmax (Tmax)
Time Frame: 15 days
|
Blood sample will be collected to evaluate PK profile of TG-1000.
|
15 days
|
area under the curve from time zero to the time (AUC0-t)
Time Frame: 15 days
|
Blood sample will be collected to evaluate PK profile and food effect of TG-1000.
|
15 days
|
area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last)
Time Frame: 15 days
|
Blood sample will be collected to evaluate PK profile of TG-1000.
|
15 days
|
area under the concentration-time curve from time zero to infinity (AUC0-inf)
Time Frame: 15 days
|
Blood sample will be collected to evaluate PK profile and food Effect of TG-1000.
|
15 days
|
terminal elimination half-life (T1/2, z)
Time Frame: 15 days
|
Blood sample will be collected to evaluate PK profile of TG-1000.
|
15 days
|
apparent total body clearance (CL/F)
Time Frame: 15 days
|
Blood sample will be collected to evaluate PK profile of TG-1000.
|
15 days
|
apparent total volume distribution (V/F)
Time Frame: 15 days
|
Blood sample will be collected to evaluate PK profile of TG-1000.
|
15 days
|
plasma concentration 24 h after dosing (C24)
Time Frame: 15 days
|
Blood sample will be collected to evaluate PK profile of TG-1000.
|
15 days
|
urinary excretion ratio relative to dose from time zero to the time (Feu0-t)
Time Frame: 15 days
|
Urine sample will be collected to evaluate PK profile of TG-1000.
|
15 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- TG-1000-C-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Chinese Volunteers
-
Harbour BioMed (Guangzhou) Co. Ltd.CompletedHealthy Chinese VolunteersChina
-
Otsuka Beijing Research InstituteCompleted
-
Astellas Pharma China, Inc.CompletedHealthy Chinese VolunteersChina
-
Lee's Pharmaceutical LimitedUnknownHealthy Chinese VolunteersChina
-
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.R&G Pharma Studies Co.,Ltd.CompletedHealthy Chinese VolunteersChina
-
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.R&G Pharma Studies Co.,Ltd.CompletedHealthy Chinese VolunteersChina
-
UCB Biopharma S.P.R.L.CompletedHealthy Male Chinese VolunteersChina
-
Central South UniversityCompletedDrug Interaction of Olmesartan in Healthy Chinese VolunteersChina
-
Allorion Therapeutics IncRecruitingChinese Healthy VolunteerChina
-
Centocor, Inc.CompletedHealthy Adult Chinese MalesChina
Clinical Trials on TG-1000
-
TaiGen Biotechnology Co., Ltd.R&G Pharma Studies Co.,Ltd.Completed
-
Kolon TissueGene, Inc.Not yet recruiting
-
Asana BioSciencesCompletedDermatitis, Atopic | Pruritus | Dermatitis EczemaUnited States, Canada
-
GPCR Therapeutics, Inc.CompletedMultiple Myeloma | Hodgkin Disease | Non-Hodgkin LymphomaTaiwan
-
GPCR Therapeutics, Inc.Completed
-
TG Therapeutics, Inc.Completed
-
TG Therapeutics, Inc.Memorial Sloan Kettering Cancer CenterCompletedChronic Lymphocytic Leukemia | Richter SyndromeUnited States
-
GPCR Therapeutics, Inc.CompletedMultiple Myeloma | Non-hodgkin's Lymphoma | Hodgkin's DiseaseUnited States
-
TaiGen Biotechnology Co., Ltd.CompletedDiabetic Foot InfectionsTaiwan, United States, South Africa, Thailand
-
TaiGen Biotechnology Co., Ltd.CompletedHealthy | Hepatitis C, ChronicUnited States